NCT02601287View on ClinicalTrials.gov

A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Urinary IncontinenceOveractive Bladder
Interventions
BIOLOGICAL

Botulinum Toxin Type A

Botulinum Toxin Type A into detrusor muscle on Day 1

Trial Locations (5)

14647

The Catholic University of Korea Bucheion St. Mary Hospital, Gyeonggi-do

49241

Pusan National University Hospital, Busan

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY